Ron Piervincenzi Named Next CEO of USP - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ron Piervincenzi Named Next CEO of USP


The Board of Trustees of the United States Pharmacopeial Convention (USP) today announced that Ron Piervincenzi will become the chief executive officer of USP and chair of USP’s standards-setting body, the Council of Experts. Piervincenzi will assume these responsibilities Feb. 1, 2014.

“I am excited and honored to lead USP’s mission to improve global health,” said Piervincenzi. “This is an outstanding organization doing life-changing work around the world, and I look forward to focusing the collective energy, expertise and knowledge of USP’s global volunteers and staff on the challenges of the future.”

“In Dr. Piervincenzi we have found an outstanding new leader for USP, which has seen unprecedented growth over the past several years,” said USP Board of Trustees Chair, Thomas R. Temple, R.Ph., M.S. “I am excited about Dr. Piervincenzi’s commitment to the next phase of USP’s unique mission to develop and promote cutting edge global standards for pharmaceuticals, food, and dietary supplements.”

Piervincenzi was a partner and leader in McKinsey & Company's Global Pharmaceutical and Medical Products Practice for 12 years where, among other responsibilities, he launched McKinsey's global drug safety, medical and regulatory service line.  Dr. Piervincenzi earned an MS and PhD from Duke University in Biomedical Engineering with research focused on protein engineering.

Source: US Pharmacopeial Convention (USP)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here